Kalaris Therapeutics, Inc.

Biotechnology • Healthcare • Palo Alto, CA, United States • KLRS (NGM)

Kalaris Therapeutics, Inc., a clinical-stage ophthalmology biotech company, engages in developing therapies for the treatment of neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was incorporated in 2019 and is based in Palo Alto, California.

628 Middlefield Road, Palo Alto, CA 94301, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Chardan Capital Initiates Coverage of Kalaris Therapeutics (KLRS) with Buy Recommendation - Nasdaq

Nasdaq • Dec 24

Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week - Yahoo Finance

Yahoo Finance • Sep 28

Kalaris Therapeutics: TH103 Trial Success And $50M Raise Set Stage For Growth (KLRS) - Seeking Alpha

Seeking Alpha • Dec 18

Chardan Capital Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Strong-Buy - MarketBeat

MarketBeat • Dec 24

80-Patient Phase 1b/2 Trial: Kalaris Tests Revolutionary AMD Drug from Lasker Award Winner - Stock Titan

Stock Titan • Sep 15

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has Kalaris Therapeutics, Inc. had layoffs?

No layoff events have been recorded for Kalaris Therapeutics, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does Kalaris Therapeutics, Inc. have?

Kalaris Therapeutics, Inc. has approximately 14 employees.

What industry is Kalaris Therapeutics, Inc. in?

Kalaris Therapeutics, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is Kalaris Therapeutics, Inc. a publicly traded company?

Yes, Kalaris Therapeutics, Inc. is publicly traded under the ticker symbol KLRS on the NGM. The company has a market capitalization of approximately $0.17 billion.

Where is Kalaris Therapeutics, Inc. headquartered?

Kalaris Therapeutics, Inc. is headquartered in Palo Alto, CA, United States at 628 Middlefield Road, Palo Alto, CA 94301, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.